Trial Profile
A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2020
Price :
$35
*
At a glance
- Drugs Palovarotene (Primary)
- Indications Fibrodysplasia ossificans progressiva
- Focus Adverse reactions
- Sponsors Clementia Pharmaceuticals
- 29 Apr 2020 Status changed from suspended to discontinued.
- 29 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 29 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.